Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adicet Bio Inc (NQ: ACET )

8.960 +0.070 (+0.79%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 265,800
Open 8.910
Bid (Size) 8.030 (1)
Ask (Size) 8.970 (1)
Prev. Close 8.890
Today's Range 8.859 - 9.145
52wk Range 7.420 - 21.87
Shares Outstanding 42,851,342
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday's session saw 16 companies set new 52-week lows. 
Via Benzinga
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire

Performance

YTD
+4.55%
+4.55%
1 Month
+10.62%
+10.62%
3 Month
-47.88%
-47.88%
6 Month
-46.95%
-46.95%
1 Year
-22.29%
-22.29%

More News

Read More
Peering Into Adicet Bio's Recent Short Interest
Via Benzinga
Dow Surges Over 250 Points; Weber Shares Spike Higher
Via Benzinga
Stocks Hold Gains Ahead Of Tuesday's Economic Flurry
Via Talk Markets
Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Rises Sharply; Adicet Bio Shares Plunge
Via Benzinga
RH, HUYA, Bilibili And Some Other Big Stocks Moving Lower On Monday
Via Benzinga
Adicet Bio Shares Fall After Underwhelming Data From Non-Hodgkin's Lymphoma Study
Via Benzinga
US Stocks Higher; Dow Rises Over 100 Points
Via Benzinga
Why Aptevo Therapeutics Shares Are Trading Higher By More Than 100%; Here Are 28 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summit
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Appoints Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer
From Adicet Bio, Inc.
Via Business Wire
Gamma Delta T Cell Therapy Market Could Reach $4 Billion As Biotechs Race To Get Breakthrough Cancer Treatment Approved
Via Benzinga
Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday
Via Benzinga
Target, Holley, Ferroglobe And Other Big Losers From Wednesday
Via Benzinga
Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Showcases Preclinical Data for Four New Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
From Adicet Bio, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.